An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group

Total Page:16

File Type:pdf, Size:1020Kb

An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group International Journal of Molecular Sciences Review The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group Margherita De Rosa * , Anna Verdino, Annunziata Soriente and Anna Marabotti * Department of Chemistry and Biology “A. Zambelli”, University of Salerno, 84084 Fisciano (SA), Italy; [email protected] (A.V.); [email protected] (A.S.) * Correspondence: [email protected] (M.D.R.); [email protected] (A.M.); Tel.: +39-089-969553 (M.D.R.); +39-089-969583 (A.M.) Abstract: β-lactam antibiotics are among the most important and widely used antimicrobials world- wide and are comprised of a large family of compounds, obtained by chemical modifications of the common scaffolds. Usually these modifications include the addition of active groups, but less frequently, molecules were synthesized in which either two β-lactam rings were joined to create a single bifunctional compound, or the azetidinone ring was joined to another antibiotic scaffold or another molecule with a different activity, in order to create a molecule bearing two different pharmacophoric functions. In this review, we report some examples of these derivatives, highlighting their biological properties and discussing how this strategy can lead to the development of innovative antibiotics that can represent either novel weapons against the rampant increase of antimicrobial resistance, or molecules with a broader spectrum of action. Keywords: bis-azetidinone derivatives; dual antibiotics; podands; siderophores; bis beta-lactam; bis beta-lactam macrocycles Citation: De Rosa, M.; Verdino, A.; Soriente, A.; Marabotti, A. The Odd 1. Introduction Couple(s): An Overview of β-lactam antibiotics are a broad group of molecules that are naturally produced by Beta-Lactam Antibiotics Bearing different organisms (molds belonging to Penicillium spp. and Cephalosporium spp. for More Than One Pharmacophoric penicillins and cephalosporins, respectively, and bacteria belonging to different species for Group. Int. J. Mol. Sci. 2021, 22, 617. monobactams and carbapenems) (Figure1). https://doi.org/10.3390/ The serendipitous discovery of the first representative of this broad group of molecules, ijms22020617 penicillin G, is generally attributed to Alexander Fleming in 1929 [1], although there are pieces of evidence that, about fifteen years before, an Italian physician, Vincenzo Tiberio, Received: 14 December 2020 Accepted: 6 January 2021 had already identified in molds a “principle with bactericidal action” [2]. Only in 1949, Published: 9 January 2021 however, was the structure of this compound fully revealed, thanks to the pioneering X-ray studies of Dorothy Crowfoot Hodgkin [3]. Another Italian pharmacologist, Giuseppe Publisher’s Note: MDPI stays neu- Brotzu, identified the presence of other compounds with bactericidal activity in crude fil- tral with regard to jurisdictional clai- trates of Cephalosporium cultures in 1945 [4]. The founder of this second class of compounds, ms in published maps and institutio- cephalosporin C, was identified from these filtrates in 1953 and its structure was fully char- nal affiliations. acterized in 1961 [5,6]. The other classes of β-lactam antibiotics, namely carbapenems and monobactams, were discovered more recently [7,8], in an effort to identify new members of this broad group of molecules. All these compounds share a common chemical moiety, i.e., a four-member ring with Copyright: © 2021 by the authors. Li- an amidic function, commonly called “β-lactam ring” or “azetidinone”. In penicillins, censee MDPI, Basel, Switzerland. cephalosporins, and carbapenems, this ring is fused to another 5- or 6-member ring, This article is an open access article whereas in monobactams, the β-lactam ring is monocyclic (Figure1). This moiety is the distributed under the terms and con- mainly responsible for the antibacterial properties of all these molecules, due to their ditions of the Creative Commons At- ability to block the bacterial cell wall synthesis as a result of their covalent binding to tribution (CC BY) license (https:// creativecommons.org/licenses/by/ penicillin-binding proteins (PBPs), which are essential enzymes involved in the terminal 4.0/). steps of the synthesis of peptidoglycan, the main component of the bacterial cell wall [9]. Int. J. Mol. Sci. 2021, 22, 617. https://doi.org/10.3390/ijms22020617 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021, 22, 617 2 of 21 ity to block the bacterial cell wall synthesis as a result of their covalent binding to penicil- Int. J. Mol. Sci. 2021, 22, 617 2 of 21 lin-binding proteins (PBPs), which are essential enzymes involved in the terminal steps of the synthesis of peptidoglycan, the main component of the bacterial cell wall [9]. Figure 1. CoreCore structures structures of of different different classes classes of ofβ-lactamβ-lactam antibiotics. antibiotics. In penicillins, In penicillins, the theβ-lactamβ-lactam moiety moiety is fused is fused to a five- to a memberfive-member thiazolidine thiazolidine ring; ring;in cephalosporins, in cephalosporins, the β the-lactamβ-lactam moiety moiety is fused is fused to a six-member to a six-member dihydrothiazine dihydrothiazine ring; ring; in car- in bapenems,carbapenems, the theβ-lactamβ-lactam moiety moiety is fused is fused to a topyrroline a pyrroline ring; ring; in monobactams, in monobactams, the β the-lactamβ-lactam ring is ring not isfused not fusedto any to other any ring. In all classes, the β-lactam moiety is highlighted in red; the standard numbering of the nucleus for each class is also other ring. In all classes, the β-lactam moiety is highlighted in red; the standard numbering of the nucleus for each class is reported. also reported. AfterAfter the the so-called so-called “Golden “Golden Age” Age” of antibiotic of antibiotic discovery discovery (from (from the 1940s the 1940sto the 1960s) to the [10],1960s) researchers [10], researchers had to realize had to the realize progressiv the progressivee increase increase of microorganisms of microorganisms that are thatnot susceptiveare not susceptive to the action to the of action these ofdrugs. these This drugs. resistance This resistance is caused is causedby the development by the develop- of manyment ofdifferent many different“escape “escapestrategies”, strategies”, such as the such alteration as the alteration of the target, of the the target, development the devel- ofopment pumps of to pumps export tothe export antibiotics the antibioticsoutside the outside microbial the cell, microbial and in particular cell, and infor particular β-lactam antibiotics,for β-lactam the antibiotics, widespread the diffusion widespread of β diffusion-lactamases, of β enzymes-lactamases, able enzymes to inactivate able totheir in- pharmacophoricactivate their pharmacophoric core by hydrolysis core of by the hydrolysis β-lactam of ring the [11].β-lactam Therefore, ring [during11]. Therefore, the last decades,during the a huge last decades,effort has abeen huge made effort worldwid has beene to made identify worldwide or synthesize to identify new antibiotics, or synthe- ablesize to new encompass antibiotics, the ableantimicrobial to encompass resistance the antimicrobial that has been resistancerecently declared that has by been WHO re- “onecently declaredof the by WHOtop 10 “one global of the toppublic 10 global health public healththreats threats facing facing humanity” humanity” (https://www.who.int/news-room/fact-sheets/deta(https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistanceil/antimicrobial-resistance; declaration; declara- oftion 13 ofOctober 13 October 2020). 2020). Additionally, Additionally, several several derivatives derivatives of the of natural the natural compounds compounds have been have createdbeen created to modulate to modulate their pharmacokinetic their pharmacokinetic properties properties and/or and/or to widen to their widen spectrum their spec- of action.trum of For action. example, For example, to date, hundreds to date, hundreds of cephalosporin of cephalosporin derivatives derivatives are available are availableand they areand classified they are classifiedinto five “generations” into five “generations” that are characterized that are characterized by different by different ways of waysadmin- of istrationadministration and by andan enhanced by an enhanced microbicidal microbicidal activity activity towards towards Gram-negative Gram-negative bacteria bacteria (while the(while founder the founder molecule molecule is mainly is mainlyactive on active Gram-positive on Gram-positive bacteria) bacteria) [12]. [12]. TheThe total synthesis of β-lactam-lactam antibiotics antibiotics in in the the laboratory laboratory is is difficult difficult because these molecules,molecules, despite despite their their limited limited size, size, are are ofte oftenn extremely extremely complex complex in infunction function and and chirality chiral- [13].ity [ 13Therefore,]. Therefore, the vast the vastmajority majority of the of chemical the chemical modifications modifications applied applied to β-lactam to β-lactam anti- bioticsantibiotics involve involve the functionalization the functionalization of the of pharmacophoric the pharmacophoric core, core, typical typical of each of each class, class, us- ingusing the the total total chemical chemical or or enzyme-assisted enzyme-assisted strategi strategies.es. Each Each of of the the 1, 1, 2, 2, 3, 3, or or 4 4 positions positions on thethe β-lactam-lactam ring ring (Figure (Figure 11)) havehave beenbeen
Recommended publications
  • Chiral Proton Catalysis: Design and Development of Enantioselective Aza-Henry and Diels-Alder Reactions
    CHIRAL PROTON CATALYSIS: DESIGN AND DEVELOPMENT OF ENANTIOSELECTIVE AZA-HENRY AND DIELS-ALDER REACTIONS Ryan A. Yoder Submitted to the faculty of the University Graduate School in partial fulfillment of the requirements for the degree Doctor of Philosophy in the Department of Chemistry, Indiana University June 2008 Accepted by the Graduate Faculty, Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Doctoral Committee _____________________________ Jeffrey N. Johnston, Ph.D. _____________________________ Daniel J. Mindiola, Ph.D. _____________________________ David R. Williams, Ph.D. _____________________________ Jeffrey Zaleski, Ph.D. April 24, 2008 ii © 2008 Ryan A. Yoder ALL RIGHTS RESERVED iii DEDICATION This work is dedicated to my parents, David and Doreen Yoder, and my sister, LeeAnna Loudermilk. Their unwavering love and support provided the inspiration for me to pursue my dreams. The sacrifices they have made and the strength they have shown continue to motivate me to be a better person each and every day. Thank you mom, dad, and little sis for being the rocks that I can lean on and the foundation that allowed me to find the happiness I have today. Without you, none of this would have been possible. iv ACKNOWLEDGEMENTS First and foremost I want to thank my research advisor, Professor Jeffrey N. Johnston. I am incredibly grateful for his mentoring and guidance throughout my time in the Johnston group. He has instilled in me a solid foundation in the fundamentals of organic chemistry and at the same time has taught me how to apply innovative and creative solutions to complex problems.
    [Show full text]
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Novel Antimicrobial Agents Inhibiting Lipid II Incorporation Into Peptidoglycan Essay MBB
    27 -7-2019 Novel antimicrobial agents inhibiting lipid II incorporation into peptidoglycan Essay MBB Mark Nijland S3265978 Supervisor: Prof. Dr. Dirk-Jan Scheffers Molecular Microbiology University of Groningen Content Abstract..............................................................................................................................................2 1.0 Peptidoglycan biosynthesis of bacteria ........................................................................................3 2.0 Novel antimicrobial agents ...........................................................................................................4 2.1 Teixobactin ...............................................................................................................................4 2.2 tridecaptin A1............................................................................................................................7 2.3 Malacidins ................................................................................................................................8 2.4 Humimycins ..............................................................................................................................9 2.5 LysM ........................................................................................................................................ 10 3.0 Concluding remarks .................................................................................................................... 11 4.0 references .................................................................................................................................
    [Show full text]
  • Brilacidin First-In-Class Defensin-Mimetic Drug Candidate
    Brilacidin First-in-Class Defensin-Mimetic Drug Candidate Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment April 20, 2020 Page # I. Brilacidin: Background Information 2 II. Brilacidin: Two Primary Mechanisms of Action 3 Membrane Disruption 4 Immunomodulatory 7 III. Brilacidin: Several Complementary Ways of Targeting COVID-19 10 Antiviral (anti-SARS-CoV-2 activity) 11 Immuno/Anti-Inflammatory 13 Antimicrobial 16 IV. Brilacidin: COVID-19 Clinical Development Pathways 18 Drug 18 Vaccine 20 Next Steps 24 V. Brilacidin: Phase 2 Clinical Trial Data in Other Indications 25 VI. AMPs/Defensins (Mimetics): Antiviral Properties 30 VII. AMPs/Defensins (Mimetics): Anti-Coronavirus Potential 33 VIII. The Broader Context: Characteristics of the COVID-19 Pandemic 36 Innovation Pharmaceuticals 301 Edgewater Place, Ste 100 Wakefield, MA 01880 978.921.4125 [email protected] Innovation Pharmaceuticals: Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment (April 20, 2020) Page 1 of 45 I. Brilacidin: Background Information Brilacidin (PMX-30063) is Innovation Pharmaceutical’s lead Host Defense Protein (HDP)/Defensin-Mimetic drug candidate targeting SARS-CoV-2, the virus responsible for COVID-19. Laboratory testing conducted at a U.S.-based Regional Biocontainment Laboratory (RBL) supports Brilacidin’s antiviral activity in directly inhibiting SARS-CoV-2 in cell-based assays. Additional pre-clinical and clinical data support Brilacidin’s therapeutic potential to inhibit the production of IL-6, IL-1, TNF- and other pro-inflammatory cytokines and chemokines (e.g., MCP-1), identified as central drivers in the worsening prognoses of COVID-19 patients.
    [Show full text]
  • A Small Outbreak of Third Generation Cephem-Resistant Citrobacter
    Jpn. J. Infect. Dis., 57, 2004 Laboratory and Epidemiology Communications A Small Outbreak of Third Generation Cephem-Resistant Citrobacter freundii Infection on a Surgical Ward Toshi Nada*, Hisashi Baba, Kumiko Kawamura2, Teruko Ohkura, Keizo Torii1 and Michio Ohta1 Department of Clinical Laboratory, Nagoya University Hospital, Nagoya 466-8560, 1Department of Bacteriology, Nagoya University Graduate School of Medicine, Nagoya 466-8550 and 2Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya 461-8673 Communicated by Yoshichika Arakawa (Accepted June 11, 2004) Citrobacter freundii is a member of family Enterobacteri- from those of type a and b strains. aceae and has been associated with nosocomial infections As previous studies have indicated, third generation in the urinary, respiratory, and biliary tracts of debilitated cephem-resistance of Gram-negative bacteria are due to the hospital patients. C. freundii has an inducible chromosomally hydrolysis of β-lactams by β-lactamases. These β-lactamases encoded cephalosporinase that can inactivate cephamycins include extended spectrum β-lactamase (ESBL), metallo- and cephalosporins. However, most clinical isolates are β-lactamase, and plasmid-encoded AmpC cephalosporinase sensitive to new third generation cephems and carbapenems. (1-3). ESBL confers variable levels of resistance to cefotaxime, We report here a small outbreak of infection caused by ceftazidime, and other broad-spectrum cephalosporins and third generation cephem-resistant C. freundii on a surgical to monobactams, but has no detectable activity against ward of a university hospital in 2002. We identified four cephamycins and carbapenems, and is relatively sensitive patients with biliary infection and two carrier patients during to sulbactam (1). Plasmid-encoded metallo-β-lactamase July and October.
    [Show full text]
  • General Items
    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
    [Show full text]
  • Structure of a Penicillin Binding Protein Complexed with a Cephalosporin-Peptidoglycan Mimic M.A
    Structure of a Penicillin Binding Protein Complexed with a Cephalosporin-Peptidoglycan Mimic M.A. McDonough1, W. Lee2, N.R. Silvaggi1, L.P. Kotra 2, Z-H. Li2, Y. Takeda2, S .O. Mobashery2, and J.A. Kelly1 1Department of Molecular and Cell Biology and Institute for Materials Science, Univ. of Connecticut, Storrs, CT 2Institute for Drug Design and the Department of Chemistry, Wayne State Univ., Detroit, MI Many bacteria that are responsible for causing dis- lactams. Also, one questions why ß-lactamases hydro- eases in humans are rapidly developing mutant strains lyze ß-lactams and release them rapidly but they do resistant to existing antibiotics. Proliferation of these not react with peptide substrates. mutant strains is likely to be a serious health-care prob- To help answer these questions, structural studies lem of increasing proportions. Almost sixty percent of of the Streptomyces sp. R61 D-Ala-D-Ala-peptidase all clinically used antibiotics are beta-lactams, which have been undertaken to investigate how the enzyme stop the growth of bacteria by interfering with their cell- wall biosynthesis. The cell walls are made of glycan chains that polymerize to form a structure that gives strength and shape to the bacteria. An understanding of the process how the cell wall is synthesized may help in designing more potent antibiotics. D-Ala-D-Ala-carboxypeptidase/transpeptidases (DD-peptidases) are penicillin-binding proteins (PBPs), the targets of ß-lactam antibiotics such as penicillins and cephalosporins (Figure 1A). These enzymes cata- lyze the final cross-linking step of bacterial cell wall bio- synthesis. In vivo inhibition of PBPs by ß-lactams re- sults in the cessation of bacterial growth.
    [Show full text]
  • Sepsis Caused by Newly Identified Capnocytophaga Canis Following Cat Bites: C
    doi: 10.2169/internalmedicine.9196-17 Intern Med 57: 273-277, 2018 http://internmed.jp 【 CASE REPORT 】 Sepsis Caused by Newly Identified Capnocytophaga canis Following Cat Bites: C. canis Is the Third Candidate along with C. canimorsus and C. cynodegmi Causing Zoonotic Infection Minami Taki 1, Yoshio Shimojima 1, Ayako Nogami 2, Takuhiro Yoshida 1, Michio Suzuki 3, Koichi Imaoka 3, Hiroki Momoi 1 and Norinao Hanyu 1 Abstract: Sepsis caused by a Capnocytophaga canis infection has only been rarely reported. A 67-year-old female with a past medical history of splenectomy was admitted to our hospital with fever and general malaise. She had been bitten by a cat. She showed disseminated intravascular coagulation and multi-organ failure because of severe sepsis. On blood culture, characteristic gram-negative fusiform rods were detected; therefore, a Capnocytophaga species infection was suspected. A nucleotide sequence analysis revealed the species to be C. canis, which was newly identified in 2016. C. canis may have low virulence in humans; however, C. canis with oxidase activity may cause severe zoonotic infection. Key words: Capnocytophaga canis, Capnocytophaga canimorsus, sepsis, oxidase activity (Intern Med 57: 273-277, 2018) (DOI: 10.2169/internalmedicine.9196-17) Introduction Case Report The genus Capnocytophaga consists of gram-negative A 67-year-old woman was admitted to our hospital with rod-shaped bacteria that reside in the oral cavities of humans general malaise and fever for 3 days starting the day after and domestic animals. Capnocytophaga formerly comprised being bitten by a cat on both her hands. She had a medical eight species (1, 2).
    [Show full text]
  • Catalytic, Asymmetric Synthesis of Β-Lactams
    J. Am. Chem. Soc. 2000, 122, 7831-7832 7831 Catalytic, Asymmetric Synthesis of â-Lactams Table 1. Diastereoselectivity in the Nucleophile-Catalyzed Reaction of Methylphenylketene 3b with Imine 2a Andrew E. Taggi, Ahmed M. Hafez, Harald Wack, Brandon Young, William J. Drury, III, and Thomas Lectka* Department of Chemistry Johns Hopkins UniVersity, 3400 North Charles Street Baltimore, Maryland 21218 ReceiVed May 22, 2000 The paramount importance of â-lactams (1) to pharmaceutical science and biochemistry has been well established.1 New chiral â-lactams are in demand as antibacterial agents, and their recent discovery as mechanism-based serine protease inhibitors2 has kept interest in their synthesis at a high level.3 However, most chiral methodology is auxiliary-based; only one catalytic, asymmetric synthesis of the â-lactam ring system is known, affording product a - ° in modest enantioselectivity.4 Many asymmetric auxiliary-based Reactions run with 10 mol% catalyst at 78 C and allowed to slowly warm to room temperature overnight. â-lactam syntheses rely on the reaction of imines with ketenes, a 3 process that generally proceeds without a catalyst. We recently catalyzed by 10 mol % bifunctional amine 4a gave a cis/trans dr accomplished a catalyzed reaction of imines and ketenes by of 3/97. A significant role for the H-bond contact in 4a is sug- making the imine component non-nucleophilic, as in electron- gested, as the sterically similar catalyst 4b, which does not contain deficient imino ester 2a.5 In this contribution, we report the ) 6 a hydrogen bond donor, gave low diastereoselectivity (dr 34/ catalytic, asymmetric reaction of imine 2a and ketenes 3 to 66).
    [Show full text]
  • Penicillin Skin Testing
    Penicillin Skin Testing Penicillin Skin Testing: Frequently Asked Questions Benzylpenicilloyl Polylysine (Pre-Pen®) and Diluted Penicillin G June 2012 VA Pharmacy Benefits Management Services, Medical Advisory Panel and VISN Pharmacist Executives Benzylpenicilloyl polylysine (Pre-Pen®) was FDA approved in 2009 for the assessment of sensitization to penicillin in those patients suspected, based upon previous experience, of having a clinical hypersensitivity to penicillin. Penicillin skin testing is the most reliable way to evaluate patients for IgE-mediated penicillin allergy. Skin testing is conducted using benzylpenicilloyl polylysine (major determinant), penicillin G diluted with normal saline to 10,000 units/ml (minor determinant), a positive and negative control. Testing with both the major and minor determinant of penicillin can identify up to 97% of patients with an immediate hypersensitivity to penicillin. The intent of this document is to help guide appropriate use of penicillin skin testing. 1. WHEN IS PENICILLIN SKIN TESTING INDICATED? Penicillin skin testing can be considered in those patients with a prior history of hypersensitivity to penicillin or allergy to penicillin in situations where the provider considers penicillin the drug of choice or prefers treatment with penicillin. If skin testing is indicated, the patient should be referred to a VA Allergy Specialist or other appropriately trained physician who is experienced in the application and interpretation of PCN skin testing, as locally designated. Although approximately 10% of patients will remain allergic to penicillin their entire lives, a large majority will stop expressing penicillin-specific IgE-mediated antibodies and can be safely treated with penicillin. Skin testing with benzylpenicilloyl polylysine is contraindicated in patients who are known to be extremely hypersensitive to penicillin and in those patients who have experienced a systemic or marked local reaction to prior administration of benzylpenicilloyl polylysine.
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]